DNSP-11
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Experimental intranasal dopaminergic neuroprotection: strong animal-model signal for dopamine-neuron survival and turnover, but no human efficacy layer yet.
No human safety data exists — all evidence is from rodent and one non-human primate study; this is entirely experimental with no established safe dose for humans.
Experimental intranasal dopaminergic neuroprotection: strong animal-model signal for dopamine-neuron survival and turnover, but no human efficacy layer yet.
No adverse effects documented in animals, including primate escalation to 10 mg/day, but human risks are unknown. Watch for sleep, mood, blood pressure, or neurological changes because the receptor pathway is not identified.
Poor cost-effectiveness for most users — product availability is limited and expensive, and human efficacy remains unproven.
No human self-experimentation signal exists. The animal data is unusually focused for dopaminergic neuroprotection, but a healthy-user cognitive or longevity payoff remains unproven.
Do not stack with MAO inhibitors — combined dopaminergic enhancement carries unpredictable risk with no safety characterization.
Intro
DNSP-11 (Dopamine Neuron Stimulating Peptide-11) is an 11-amino-acid peptide with the sequence PPEAPAEDRSL-amide, derived from the pro-domain of Glial Cell Line-Derived Neurotrophic Factor (GDNF).
GDNF is one of the most potent known survival factors for dopaminergic neurons, but the role of its proregion was historically dismissed as a mere biosynthetic scaffold. Research from the Gerhardt laboratory at the University of Kentucky challenged that assumption, demonstrating that the proGDNF domain produces a biologically active fragment with independent neurotrophic activity.
DNSP-11 was first identified for stimulating synaptic transmission in hippocampal neurons — an effect not expected from a precursor peptide presumed inert. Subsequent work characterized potent neuroprotective and neurotrophic actions directed at dopaminergic neurons in vitro and in rodent Parkinson's disease models. Critically, DNSP-11 does not bind the canonical GFRalpha1/RET receptor complex that GDNF uses, indicating a distinct and as-yet unidentified signaling pathway. ERK1/2 phosphorylation is the primary identified downstream event.
DNSP-11's entire evidence base is preclinical — in vitro cell studies, rodent 6-OHDA lesion models, and one unpublished non-human primate MPTP study. No Phase 1 human trials have been published. The compound has attracted interest from the biohacking community as an intranasal neuropeptide for dopaminergic support, with community protocols extrapolating from animal data. The intranasal route is critical: DNSP-11 has a plasma half-life under 12 minutes in rats, making systemic delivery pharmacokinetically impractical for CNS targeting. Olfactory transport following intranasal instillation delivers it to the striatum and substantia nigra within 30 minutes.
Researchers Bradley and Gerhardt frame DNSP-11 as a proof-of-concept for a broader category of neurotrophic factor propeptides — small, synthesizable molecules with GDNF-analogous neuroprotective activity but independent signaling profiles. Whether this translates to human benefit remains to be demonstrated.
Observed Effects
Dopaminergic neuron survival (in vitro): In fetal rat mesencephalic neuron cultures, DNSP-11 increased surviving cell counts approximately 75% above vehicle control and enhanced neuritic outgrowth.
In MN9D dopaminergic cells exposed to 6-OHDA neurotoxin, pretreatment significantly reduced TUNEL-positive apoptotic cells and caspase-3 activity. A notable distinction from GDNF: DNSP-11 also protects B65 dopaminergic cells against staurosporine- and gramicidin-induced cytotoxicity under nutrient deprivation, an effect mature GDNF does not share at the same timepoint.
Dopamine enhancement (rodent, in vivo): Single intranigral injection of 30 mcg DNSP-11 in Fischer 344 rats produced sustained increases in resting dopamine (26.0 to 45.8 nM, p=0.03), DOPAC (3355 to 6544 nM, p=0.0025), and HVA (2419 to 4516 nM, p=0.001) at 28 days post-injection. Potassium-evoked DA release increased in the dorsal striatum at two weeks (vehicle 2.77 uM vs DNSP-11 4.00 uM, p<0.01). ERK1/2 phosphorylation increased more than 300% at 100 nM and more than 400% at 1 uM in MN9D cells.
6-OHDA Parkinson's model (rodent): Repeated intranasal DNSP-11 in 6-OHDA-lesioned Fischer 344 rats produced significant reductions in d-amphetamine-induced rotation, decreased dopamine turnover ratio (DOPAC/DA) in the lesioned striatum, and increased sparing of tyrosine hydroxylase (TH)-positive neurons in both the substantia nigra pars compacta and striatum. At 100 mcg intranasally in lesioned rats, nigral DA increased 74% and DOPAC 132%. DNSP-11 demonstrated efficacy in severe 6-OHDA models where full-length GDNF typically fails to produce biological effects.
Non-human primate MPTP model: A 10-week biweekly dose escalation from 0.3 to 10.0 mg/day intranasally in MPTP-lesioned rhesus macaques produced bilateral improvements in fine motor performance of the upper limbs and changes in tissue dopamine and metabolite levels. No observable adverse effects were reported at any dose.
CNS distribution: 125I-labeled DNSP-11 distributed diffusely to striatum, substantia nigra, and CSF within 30 minutes of bilateral intranasal instillation, confirming olfactory-mediated CNS delivery.
Human data: None. All effects described are from animal models.
Field Reports
Direct first-person community experience reports for DNSP-11 are not available in the accessible evidence base. No clear first-person human self-experimentation outcomes or practitioner case series are present in the retained evidence.
What exists is protocol extrapolation: community protocols have translated animal model data into human dosing recommendations (100-300 mcg/day intranasal) and cycle lengths (4-6 weeks). The cycling recommendation mirrors a general precautionary norm for research peptides rather than any documented tolerance or suppression signal from users.
The absence of community experience means there is no validation layer for the extrapolated doses — users are working entirely from animal-to-human conversions from a small number of papers. This is an unusual state even among experimental peptides: most comparable compounds have at least some user-reported subjective data. DNSP-11 does not.
For users interested in intranasal dopaminergic neuropeptides with an actual community experience record, Semax has substantially more documented self-experiment data, a longer history, and a broader evidence base for cognitive and neuroprotective applications.
Community Consensus
DNSP-11 occupies a narrow corner of the research-peptide biohacking world: users tracking Parkinson's research literature and dopaminergic neuroprotection.
It has not built the self-experimentation base that Semax, Selank, or Cerebrolysin have. The practical consensus is interest without field confirmation.
The pro-DNSP-11 case is specific: it supports dopaminergic neuron health in animal models, uses an intranasal route familiar to peptide users, and has a clean reported animal safety record through 10 mg/day in primates. The skeptical case is equally important: protocols are derivative, human dose-finding is absent, and there are no long-term user logs to show whether healthy-user cognitive or longevity goals translate.
Community databases list it beside more established dopaminergic or neuropeptide tools and note compatibility with Bromantane and 9-Me-BC, but that is not the same as a mature stack culture. Active users are few, dose ranges are borrowed from papers, and the community has not independently validated an effect window.
Risks & Monitoring
No adverse effects have been documented in any preclinical study. In the rhesus macaque MPTP study — the highest-dose and most translationally relevant study — doses from 0.3 to 10.0 mg/day intranasally over 10 weeks produced no observable adverse effects. Rodent studies likewise reported no toxicity signals.
This absence of documented adverse effects should not be read as a safety clearance for humans. The receptor through which DNSP-11 signals has not been identified, which means downstream effects — intended and unintended — cannot be predicted. Long-term effects of sustained dopaminergic upregulation through an uncharacterized CNS pathway are entirely unknown.
The community cycling protocol (4-6 weeks on, then a break) reflects a precautionary posture in the absence of long-term safety data — not any documented tolerance, suppression, or withdrawal signal. No user-reported adverse effects appear in the available evidence.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Document pre-existing neurological status before any dopaminergic-pathway compound; necessary to distinguish compound effects from pre-existing symptoms.
Dopaminergic modulation can affect cardiovascular regulation via central pathways; basic vitals monitoring is prudent given the unknown human safety profile.
CNS dopaminergic compounds can affect sleep architecture, mood, and motivation; systematic subjective tracking enables early detection of unexpected effects.
No specific metabolic effects documented; baseline CMP establishes a reference for any experimental compound use.
Avoid With
Do not combine DNSP-11 with the following. Sorted highest-severity first.
Why:MAO-B inhibitors reduce dopamine catabolism; combined with DNSP-11's documented increase in DA turnover and evoked release, the combination could produce excessive dopaminergic tone or hypertensive crisis.
What to do:Selegiline is used in Parkinson's protocols; DNSP-11 with selegiline has no safety characterization.
Why:DNSP-11 increases DA turnover and evoked release. Stacking with D2/D3 agonists, dopamine releasers, or high-dose dopamine precursors may produce additive dopaminergic excess — anxiety, agitation, sleep disruption, or dyskinesia risk in predisposed individuals.
What to do:No direct interaction evidence exists; this is mechanism-based caution given documented DA-enhancing effects in animal models.
Why:D2 receptor antagonists directly oppose DNSP-11's dopaminergic enhancement effects, likely negating any efficacy and creating an unpredictable pharmacological conflict.
What to do:Users on antipsychotics should not use DNSP-11 without physician involvement.
Protocols By Goal
Dopaminergic neuroprotection / anti-aging Dose: 100-200 mcg intranasally daily, morning. Cycle: 4-6 weeks on, 4-6 weeks off.
Stack with Semax for complementary BDNF pathway support. Monitor mood, sleep, and motivation subjectively. Precautionary cycling given no long-term human data.
General dopaminergic support / biohacking stack Dose: 200-300 mcg intranasally daily. Cycle: 4-6 weeks on/off. Community stacks include Bromantane (TH gene expression enhancement) and 9-Me-BC (dendritic growth, DA synthesis support). This combination targets multiple steps in the dopaminergic maintenance pathway. No synergy data exists — monitor for over-stimulation or sleep disruption.
Parkinson's disease research context (self-experimentation) Mirrors the animal protocol most closely. Doses up to 300 mcg/day intranasally. The primate protocol used escalating doses to 10 mg/day without adverse effects, suggesting a wide tolerance window. Human extrapolation remains speculative and use outside medical supervision in diagnosed neurological disease is high-risk.
Dosing Details
All community dosing for DNSP-11 is extrapolated from animal research — no human pharmacokinetic or dose-finding data exists. Community protocols treat the optimal rat intranasal dose (300 mcg) and the primate dose-escalation range (0.3-10 mg/day) as the primary anchors.
Observed community range: 100-200 mcg intranasally once daily in the morning is the conservative field frame; 200-300 mcg intranasally once daily is the more aggressive field frame. Cycling is usually described as 4-6 weeks on followed by 4-6 weeks off.
Route constraint: intranasal use is the only route that maps to the CNS-delivery rationale. Subcutaneous use is pharmacokinetically weak given the under-12-minute plasma half-life in rats.
Handling reality: reported use depends on peptide handling quality and consistent intranasal delivery. Exact preparation, device selection, and storage are operational details that belong in qualified sterile/clinical contexts, not casual reader instructions.
Dose rationale: the 100-300 mcg range is a cautious human translation from the rat optimal dose and primate starting dose. The primate escalation to 10 mg/day without adverse effects suggests a wide animal tolerance window, but human translation remains uncertain.
Stacks & Alternatives
Complementary neuroprotective mechanism — Semax upregulates BDNF and VEGF while DNSP-11 supports dopaminergic neurons via GFL-independent ERK1/2 pathways. Both are intranasal peptides with confirmed olfactory CNS transport, making them logistically compatible. Community-recommended pairing for dopaminergic and general neuroprotective goals.
Enhances tyrosine hydroxylase (TH) gene expression, directly supporting dopamine biosynthesis. Mechanistically additive with DNSP-11's effects on TH+ neuron sparing and DA release enhancement.
Community-reported support for dendritic growth and dopamine synthesis. Used in biohacking stacks alongside DNSP-11 for comprehensive dopaminergic support.
Alternatives
Stack Cost
Low hormonal and organ-load burden, but moderate stack tax overall because the useful lane is CNS dopaminergic modulation through an unidentified receptor with no human dose-finding.
DNSP-11 enhances dopaminergic neuron function and evoked DA release in animal models. Stacking it with other dopaminergic compounds creates an additive CNS burden that cannot be quantified without human data.
No safety-gate labs are established, but neurological, sleep, mood, and vitals tracking matter because ordinary lab panels will not catch the most plausible CNS failure mode.
DNSP-11 is often expensive relative to the evidence base. Non-clinical products raise identity, purity, and quality concerns, and the available product base is thinner than for established peptides.
- ·Avoid concurrent MAO inhibitors — additive dopaminergic risk is uncharacterized and potentially serious
- ·Clear other intranasal dopaminergic compounds before adding DNSP-11 to assess baseline response
- ·Nasal atomizer device for consistent intranasal delivery
- ·Qualified peptide-preparation support
- ·Cold-chain handling after preparation
Ordinary healthy-user use has no hormonal suppression, known organ toxicity, or documented animal toxicity, but the compound is still CNS-active, human-unstudied, and mechanistically incomplete. Escalate to specialist-only when neurological disease, psychiatric vulnerability, pregnancy, or dopaminergic medication is present.
- ·Pre-existing neurological condition
- ·Currently using any dopaminergic medication
- ·Pregnancy, conception planning, or active psychiatric instability
No known hormonal suppression or physical dependence. Stopping should produce a gradual return toward pre-use dopaminergic state with no documented withdrawal syndrome.
- ·Potential loss of any functional dopaminergic enhancement observed during use
- ·Unknown whether benefits from neuroprotection persist post-cycle
Most likely outcome given the gap between animal models and human translation. Accept null result and discontinue.
Stop compound immediately. Symptoms should resolve with discontinuation. Seek medical attention for any persistent neurological symptoms.
DNSP-11 modulates dopaminergic function through an uncharacterized pathway; interaction with dopaminergic drugs is unpredictable
CNS-active compounds with unknown receptor profiles carry disproportionate risk in neurologically compromised individuals
No reproductive toxicology data exists
Practical Setup
Product quality and handling: DNSP-11 has no approved human product, and non-clinical products create identity, purity, stability, and handling risk.
Reported protocols depend on intranasal delivery quality and peptide stability; those are operational constraints, not preparation instructions.
Biomarkers: No established compound-specific biomarkers. Subjective tracking — motivation, mood, sleep quality, and energy — is the primary monitoring tool. Document neurological baseline before starting.
When to adjust or stop: Shift timing earlier in the day if sleep disruption emerges. Reduce exposure if mood changes or anxiety appear. Any new or unexpected neurological symptom warrants stopping the compound immediately and medical consultation.
Drug interactions: No formal interaction data exists. Avoid concurrent use with dopaminergic medications (MAOIs, agonists, antipsychotics) without specialist input. See stackingConflicts for mechanism-based cautions.
Nasal-route limitations: nasal congestion can impair olfactory transport, and uneven mucosal contact makes real exposure hard to interpret. A failed trial may reflect route/quality problems rather than biology.
Mechanism Deep Dive
GDNF proprotein processing DNSP-11 is a product of post-translational processing of the human GDNF proprotein.
A processing model by Gerhardt and colleagues identified the 11-amino-acid sequence PPEAPAEDRSL-amide as a biologically active fragment released from the proregion domain during maturation of full-length GDNF. The proGDNF domain was previously assumed to be a biosynthetically inert scaffold without independent function — DNSP-11 research was the first substantive challenge to that assumption.
Non-canonical signaling pathway Mature GDNF signals through GFRalpha1 (ligand-binding subunit) in complex with RET (transmembrane receptor tyrosine kinase). DNSP-11 does NOT bind GFRalpha1 — confirmed by pull-down and ELISA analyses. Activity is not blocked by staurosporine (which blocks kinase-dependent GDNF effects), and the cellular target profile differs from mature GDNF. An unidentified receptor complex mediates DNSP-11 activity. This receptor independence from the canonical GFL complex is a key mechanistic feature that may explain DNSP-11's efficacy in severe lesion models where GDNF fails: if the GFRalpha1/RET pathway is compromised by extensive neurodegeneration, DNSP-11's alternative receptor may remain functional.
ERK1/2 activation ERK1/2 (extracellular signal-regulated kinase 1/2) phosphorylation is the primary identified downstream signaling event. In MN9D dopaminergic cells, single DNSP-11 treatment increased ERK1/2 phosphorylation more than 300% at 100 nM and more than 400% at 1 uM versus vehicle — magnitude comparable to GDNF at 1.5 nM. ERK1/2 is a central node in the Ras/MAPK cascade and drives transcription of pro-survival and neurotrophic genes. ERK1/2 activation mediates neuroprotection downstream of multiple neurotrophic factors and is an established convergence point for pro-survival signaling in dopaminergic neurons.
Mitochondrial protection In nutrient-deprived B65 dopaminergic cells, DNSP-11 prevents cytochrome c release from mitochondria — an upstream event in the intrinsic apoptosis pathway. Blocking cytochrome c release prevents downstream caspase cascade activation. Caspase-3 activity is also reduced in 6-OHDA-exposed MN9D cells after DNSP-11 treatment. This mitochondrial-level protection is partly distinct from GDNF's primary mechanism and may contribute to DNSP-11's activity against cytotoxic stressors where GDNF is ineffective.
Dopamine system enhancement Beyond pure neuroprotection, single intranigral DNSP-11 injection increases resting dopamine and its catabolites (DOPAC, HVA) at 28 days and enhances potassium-evoked dopamine release at 2 weeks. These effects indicate functional enhancement of surviving dopaminergic neurons, not just survival support. The pathway linking ERK1/2 activation to dopamine biosynthesis and release likely involves ERK1/2-dependent regulation of tyrosine hydroxylase (TH) expression — the rate-limiting enzyme in dopamine synthesis — though this specific link has not been formally demonstrated for DNSP-11.
Intranasal CNS pharmacokinetics DNSP-11's plasma half-life in rats is under 12 minutes. Systemic IV or SubQ delivery results in near-complete elimination before any meaningful brain penetration occurs. Intranasal instillation bypasses this constraint via olfactory nerve-mediated transport: axons of the olfactory neuroepithelium provide a direct anatomical conduit from the nasal mucosa to the olfactory bulb and deeper CNS structures. Radiolabeled 125I-DNSP-11 reaches the striatum, substantia nigra, and CSF within 30 minutes of bilateral intranasal delivery — a route shared with Semax, Selank, and other intranasal neuropeptides.
Proposed GDNF propeptide class Bradley and Gerhardt proposed that proregion-derived peptides of GDNF and related neurotrophic factors constitute a largely unexplored class of neuroactive molecules with independent physiological roles. DNSP-11's original discovery as a hippocampal synaptic transmission stimulator supports the view that its CNS targets extend beyond the dopaminergic system. The full endogenous function of DNSP-11 — if any, as a naturally produced proGDNF cleavage product — remains uncharacterized.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
75% increase in surviving fetal mesencephalic neuron count above vehicle control
In vitro cell survival count — does not directly translate to human dopaminergic neuroprotection
ERK1/2 phosphorylation increased >300% at 100 nM and >400% at 1 uM
Cell line ERK1/2 data; signaling response in human neurons may differ quantitatively
DA increased from 26.0 nM to 45.8 nM (p=0.03), DOPAC from 3355 to 6544 nM (p=0.0025), HVA from 2419 to 4516 nM (p=0.001) at 28 days
Intranigral injection in rats; intranasal community route is a different delivery model
Dorsal striatum potassium-evoked DA: vehicle 2.77 uM vs DNSP-11 4.00 uM (p<0.01) at two weeks
Rodent striatal evoked DA release; human evoked release response unstudied
Nigral DA increased 74% and DOPAC 132% at 100 mcg intranasal in 6-OHDA-lesioned rats
Parkinson's disease lesion model; effects in non-lesioned healthy humans are entirely unknown
Biweekly escalation from 0.3 to 10.0 mg/day over 10 weeks produced bilateral fine motor improvements and dopamine metabolite changes in MPTP macaques
Non-human primate parkinsonian model; best-available pre-human translational evidence but not a validated human dose
Optimal intranasal dose was 300 mcg in normal Fischer 344 rats for dopamine turnover increase
Rat dose-optimization study; community human protocols (100-300 mcg) are direct extrapolations from this
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.